HOXA9 and leukemia: Consistent with DOT1L loss-of-function studies, these DOT1Li also selectively inhibited expression of MLL-fusion target genes such as HOXA9 and MEIS1 and selectively killed MLL-rearranged leukemia cells and xenografted tumors (90–92, 94).